Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine

Stewart J Tepper,1 Merrilee R Johnstone2 1Department of Neurology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA, 2Prescott Medical Communications Group, Chicago, IL, USA Abstract: There is a need for fast-acting, non-oral medication options for migraine because some attacks develop rapid...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tepper SJ, Johnstone MR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	migraine triptan sumatriptan AVP-825 intranasal Onzetra Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/a410bc12c18c4b24b0d02ba73659f58d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a410bc12c18c4b24b0d02ba73659f58d
record_format	dspace
spelling	oai:doaj.org-article:a410bc12c18c4b24b0d02ba73659f58d2021-12-02T05:34:28ZBreath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine1179-1470https://doaj.org/article/a410bc12c18c4b24b0d02ba73659f58d2018-05-01T00:00:00Zhttps://www.dovepress.com/breath-powered-sumatriptan-dry-nasal-powder-an-intranasal-medication-d-peer-reviewed-article-MDERhttps://doaj.org/toc/1179-1470Stewart J Tepper,1 Merrilee R Johnstone2 1Department of Neurology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA, 2Prescott Medical Communications Group, Chicago, IL, USA Abstract: There is a need for fast-acting, non-oral medication options for migraine because some attacks develop rapidly and some are accompanied by nausea, vomiting, and gastroparesis, which can hinder oral medication uptake and absorption. The most commonly prescribed migraine medications are oral triptans, with sumatriptan as the most common. However, oral triptans are associated with adverse events (AEs) of atypical sensations that may be problematic for patients. Subcutaneous (SC) injectable sumatriptan and conventional liquid triptan nasal spray formulations are also available, but the frequency of atypical sensations is the highest with SC sumatriptan, and the intense bitter taste of conventional liquid triptan nasal spray discourages use. AVP-825 (ONZETRA® Xsail®) is an intranasal medication delivery system containing 22 mg sumatriptan nasal powder that is now available in the USA for the acute treatment of migraine with or without aura in adults. The objective of this review is to summarize the development of AVP-825, which utilizes unique features of nasal anatomy to achieve efficient absorption and reduced systemic exposure. Literature searches for “sumatriptan nasal powder”, “AVP-825”, and “sumatriptan intranasal” were conducted. Review articles and pharmacokinetic, Phase II and Phase III studies were evaluated. AVP-825 demonstrates an earlier onset of efficacy and lower rate of atypical sensations than the oral standard of care, which can be attributed to its fast absorption and low systemic exposure. AEs of abnormal taste are predominantly mild. These results confirm the initial design concept for AVP-825, which aligned pharmacokinetics, anatomy, and drug presentation in a novel device to achieve optimal outcomes for the acute treatment of migraine. Keywords: migraine, triptan, sumatriptan, AVP-825, intranasal, OnzetraTepper SJJohnstone MRDove Medical PressarticlemigrainetriptansumatriptanAVP-825intranasalOnzetraMedical technologyR855-855.5ENMedical Devices: Evidence and Research, Vol Volume 11, Pp 147-156 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	migraine triptan sumatriptan AVP-825 intranasal Onzetra Medical technology R855-855.5
spellingShingle	migraine triptan sumatriptan AVP-825 intranasal Onzetra Medical technology R855-855.5 Tepper SJ Johnstone MR Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine
description	Stewart J Tepper,1 Merrilee R Johnstone2 1Department of Neurology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA, 2Prescott Medical Communications Group, Chicago, IL, USA Abstract: There is a need for fast-acting, non-oral medication options for migraine because some attacks develop rapidly and some are accompanied by nausea, vomiting, and gastroparesis, which can hinder oral medication uptake and absorption. The most commonly prescribed migraine medications are oral triptans, with sumatriptan as the most common. However, oral triptans are associated with adverse events (AEs) of atypical sensations that may be problematic for patients. Subcutaneous (SC) injectable sumatriptan and conventional liquid triptan nasal spray formulations are also available, but the frequency of atypical sensations is the highest with SC sumatriptan, and the intense bitter taste of conventional liquid triptan nasal spray discourages use. AVP-825 (ONZETRA® Xsail®) is an intranasal medication delivery system containing 22 mg sumatriptan nasal powder that is now available in the USA for the acute treatment of migraine with or without aura in adults. The objective of this review is to summarize the development of AVP-825, which utilizes unique features of nasal anatomy to achieve efficient absorption and reduced systemic exposure. Literature searches for “sumatriptan nasal powder”, “AVP-825”, and “sumatriptan intranasal” were conducted. Review articles and pharmacokinetic, Phase II and Phase III studies were evaluated. AVP-825 demonstrates an earlier onset of efficacy and lower rate of atypical sensations than the oral standard of care, which can be attributed to its fast absorption and low systemic exposure. AEs of abnormal taste are predominantly mild. These results confirm the initial design concept for AVP-825, which aligned pharmacokinetics, anatomy, and drug presentation in a novel device to achieve optimal outcomes for the acute treatment of migraine. Keywords: migraine, triptan, sumatriptan, AVP-825, intranasal, Onzetra
format	article
author	Tepper SJ Johnstone MR
author_facet	Tepper SJ Johnstone MR
author_sort	Tepper SJ
title	Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine
title_short	Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine
title_full	Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine
title_fullStr	Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine
title_full_unstemmed	Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine
title_sort	breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/a410bc12c18c4b24b0d02ba73659f58d
work_keys_str_mv	AT teppersj breathpoweredsumatriptandrynasalpowderanintranasalmedicationdeliverysystemforacutetreatmentofmigraine AT johnstonemr breathpoweredsumatriptandrynasalpowderanintranasalmedicationdeliverysystemforacutetreatmentofmigraine
_version_	1718400368176529408

Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine

Ejemplares similares